Variables | All included patients (n = 1464) | |
---|---|---|
Relative risk (95% CI) | P | |
Age (years) | 1.010 (0.982–1.039) | 0.488 |
Male | 0.534 (0.261–1.091) | 0.085 |
BMI (kg/m2) | 1.036 (0.890–1.206) | 0.649 |
Child-Pugh score | 1.177 (0.858–1.615) | 0.312 |
WBC (109/L) | 0.939 (0.791–1.115) | 0.472 |
sCr (μmol/L) | 0.997 (0.980–1.015) | 0.754 |
Alb (g/L) | 1.023 (0.971–1.077) | 0.402 |
PT (s) | 0.953 (0.843–1.078) | 0.444 |
TB (μmol/L) >2ULN | 1.954 (0.858–4.451) | 0.111 |
HB (g/dl) <100 g/L | 1.229 (0.411–3.669) | 0.712 |
ALT (u/L) ≤49 | 0.398 (0.212–0.748) | 0.004 |
AST (u/L) >67 | 2.246 (1.213–4.160) | 0.010 |
Plt (109/L) ≤114 | 0.389 (0.207–0.732) | 0.003 |
Serum AFP (ng/mL) > 400 | 1.291 (0.649–2.568) | 0.467 |
Number of tumor ≥2 | 1.071 (0.563–2.034) | 0.835 |
Maximum tumor diameter (mm) >80 | 0.816 (0.438–1.521) | 0.523 |
HIV | 0.877 (0.434–1.772) | 0.715 |
CD3+ T cells (/μL) | 0.999 (0.998–1.000) | 0.134 |
CD4+ T cells (/μL) ≤449 | 0.326 (0.174–0.611) | <0.001 |
CD8+ T cells (/μL) | 0.998 (0.997–1.000) | 0.084 |
CD4+/CD8+ | 0.676 (0.403–1.135) | 0.138 |
APRI >1.22 | 2.872 (1.537–5.366) | 0.001 |
FIB-4 > 5.39 | 3.404 (1.697–6.829) | 0.001 |
CD4/APRI ≤619.97 | 0.108 (0.420–0.278) | <0.001 |
CD4/FIB-4 ≤ 145.93 | 0.203 (0.103–0.399) | <0.001 |